Value Sense
LBPH
Longboard Pharmaceuticals, Inc. (LBPH)
Last Price$60.00.0%
Market Cap$2,336.7M
EV/Revenue LTM
118,203.7x
5Y avg
19,953.6x
Biotechnology industry median
3.7x
Stock quality & Intrinsic value
6/10
(0.8%) overvalued
LBPH
is (81.3%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Longboard Pharmaceuticals, Inc. EV/Revenue LTM

Annual
Quarterly
Daily
Crunching data... Almost there!
Dec'21Dec'22Dec'23
EV/Revenue LTM
0.0x
0.0x
0.0x
LBPH
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for LBPH and see if it's the right time to invest.
Dive in

Longboard Pharmaceuticals, Inc. (LBPH) EV/Revenue LTM comparison analysis

General

LTM EV/Revenue LTM

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Longboard Pharmaceuticals, Inc. logo
Longboard Pharmaceuticals, Inc.LBPH
256,495.0x
N/A
(4.8%)
N/A
Median Peer Set
4.0x
14.8%
(19.3%)
7.5%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
13.0x
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
10.9x
11.7%
N/A
(4.9%)
Royalty Pharma plc logo
Royalty Pharma plcRPRX
9.0x
(3.8%)
(43.7%)
37.9%
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
4.5x
18.0%
139.3%
15.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
4.3x
8.3%
10.4%
31.1%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
BioNTech SE logo
BioNTech SEBNTX
2.0x
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)

LBPH key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.00.00.0
Gross Profit
% margin
0.0
0.0%
(0.0)
0.0%
(0.0)
0.0%
(0.0)
0.0%
Operating Expenses14.427.844.856.8
Research & Development Expenses (R&D)4.619.834.643.8
Selling, General & Administrative Expenses (SG&A)9.88.110.213.0
Operating Income
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%
Interest Income0.00.10.82.4
Interest Expense0.00.00.80.0
Pre-tax Income(14.4)(27.8)(43.9)(54.4)
Income Tax
% effective tax rate
(0.0)
0.1%
(0.1)
0.2%
(0.9)
1.9%
0.0
0.0%
Net Income
% margin
(14.4)
0.0%
(27.7)
0.0%
(43.1)
0.0%
(54.4)
0.0%
EPS(0.82)(1.62)(2.51)(2.39)
Diluted EPS(0.82)(1.62)(2.51)(2.39)
EBITDA
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Longboard Pharmaceuticals, Inc.'s EV/Revenue LTM?

As of today, Microsoft Corp's last 12-month EV/Revenue LTM is 118,203.7x, based on the financial report for Sep 27, 2024 (Q3’2024). The average annual EV/Revenue LTM for Longboard Pharmaceuticals, Inc. have been 19,953.6x over the past three years, and 14,965.2x over the past five years.

2) Is Longboard Pharmaceuticals, Inc.'s EV/Revenue LTM Good?

As of today, Longboard Pharmaceuticals, Inc.'s EV/Revenue LTM is 118,203.7x, which is higher than industry median of 3.7x. It indicates that Longboard Pharmaceuticals, Inc.'s EV/Revenue LTM is Bad.

3) How does Longboard Pharmaceuticals, Inc.'s EV/Revenue LTM compare to its peers?

As of today, Longboard Pharmaceuticals, Inc.'s EV/Revenue LTM is 118,203.7x, which is higher than peer median of 4.0x. The list of peers includes ALNY, VRTX, RPRX, BMRN, REGN, UTHR, BNTX, BGNE, SMMT, ARGX.